June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
S, C.
Author:
S.B. M C,
Author:
S?hmidt, A.
Author:
Sá Pereira, I.
Author:
Saad, A.
Author:
Saavedra, D.

PB2124 OVERALL SURVIVAL OF MULTIPLE MYELOMA (MM) PATIENTS IN COLOMBIA: REPORT OF THE COLOMBIAN REGISTRY FOR HEMATO-ONCOLOGICAL DISEASES (RENEHOC) ASOCIACIÓN COLOMBIANA DE HEMATOLOGÍA Y ONCOLOGÍA (ACHO)

Melo, C. Sossa; Abello, V.; Idrobo, H.; More

HemaSphere. 3(S1):956-957, June 2019.

Author:
Saavedra, S.

PF750 SEVERE INFECTIONS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS RECEIVING POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXIS: HAPLOIDENTICAL VS MATCHED RELATED OR UNRELATED DONOR TRANSPLANTATION

Bosch-Vilaseca, A.; García-Cadenas, I.; Esquirol, A.; More

HemaSphere. 3(S1):329, June 2019.

PB1660 FLOW CYTOMETRY CHALLENGE FOR MEASURABLE RESIDUAL DISEASE MONITORING IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS RECEIVING TARGETED IMMUNOTHERAPY

Bermejo, A. Yeguas; García-Sancho, A. Martín; Morón, N. Puig; More

HemaSphere. 3(S1):768, June 2019.

Author:
Sabatelli, S.

PF644 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP)

Mele, A.; Prete, E.; De Risi, C.; More

HemaSphere. 3(S1):275-276, June 2019.

Author:
Sabattini, E.

PS928 “3C-UP” A NEW ADULT PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUBGROUP: NOVEL MOLECULAR MARKERS

Ferrari, A.; Vitali, S.; Robustelli, V.; More

HemaSphere. 3(S1):418, June 2019.

Author:
Saberi, M.
Author:
Sabir, M.
Author:
Sabirou, F.

PS1406 WEEKLY CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE UNTIL PROGRESSION IN RELAPSED REFRACTORY MULTIPLE MYELOMA

Gruchet, C.; Richez, V.; Guidez, S.; More

HemaSphere. 3(S1):646, June 2019.

Author:
Sabljic, N.
Author:
Sabol, I.

PF773 LOWER SERUM LEVELS OF ZINC AND MAGNESIUM ARE ASSOCIATED WITH WORSE ORAL CGVHD AND DYSGEUSIA IN CGVHD PATIENTS

Mravak-Stipetic, M.; Radman, M.; Desnica, L.; More

HemaSphere. 3(S1):341, June 2019.

Author:
Sabri, A.
Author:
Sacchi, M.

S821 NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: 2-YEAR EXTENDED FOLLOW-UP FROM COHORT D OF THE PHASE 2 CHECKMATE 205 STUDY

Domingo-Domènech, E.; Ramchandren, R.; Rueda, A.; More

HemaSphere. 3(S1):363, June 2019.

S822 NIVOLUMAB AND BRENTUXIMAB VEDOTIN-BASED, RESPONSE-ADAPTED TREATMENT IN PRIMARY REFRACTORY AND IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN CHECKMATE 744

Leblanc, T.; Harker-Murray, P.; Mauz-Körholz, C.; More

HemaSphere. 3(S1):363-364, June 2019.

Author:
Sacedón, R.

PS1186 CURRENT DOSE RECOMMENDATIONS FOR PONATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS CAN DIMINISH ADVERSE EVENTS WHILE MAINTAINING EFFICACY

Garcia-Gutierrez, V.; Hernandez-Boluda, J.C.; Moiraghi, B.; More

HemaSphere. 3(S1):540-541, June 2019.

Author:
Sacha, T.

PF411 ENESTOP 192-WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) FOLLOWING SECOND-LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML)

Mahon, F.-X.; Boquimpani, C.; Takahashi, N.; More

HemaSphere. 3(S1):158, June 2019.

Author:
Sachanas, S.

PS1258 CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CLINICAL SIGNIFICANCE OF ABSOLUTE CLONAL B CELL COUNTS

Kalpadakis, C.; Pangalis, G.; Konstantinou, I.; More

HemaSphere. 3(S1):575, June 2019.

PB1895 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WITH INCREASED SERUM VON WILLEBRAND LEVELS AT DIAGNOSIS HAVE A SHORTER TIME TO TREATMENT

Tryfou?., ; Papaioannou, P.; Repousis, P.; More

HemaSphere. 3(S1):863-864, June 2019.

PF638 VENOUS AND ARTERIAL THROMBOTIC EVENTS IN MYELOMA PATIENTS TREATED WITH IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE (IRD) OR LENALIDOMIDE AND DEXAMETHASONE (RD)

Sayar, Z.; Yi, K.; Cheesman, S.; More

HemaSphere. 3(S1):272, June 2019.

PB2127 BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

Mahmood, A. S.; Sachchithanantham, S.; Harrison, S.; More

HemaSphere. 3(S1):958, June 2019.

Author:
Sacher, J.
Author:
Sachs, C.

PB1762 A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY PLUS MIDOSTAURIN (PKC412) OR PLACEBO IN NEWLY DIAGNOSED PATIENTS WITH FLT3 MUTATION NEGATIVE AML

Döhner, H.; Lo-Coc, F.; Ossenkoppele, G.; More

HemaSphere. 3(S1):809-810, June 2019.

PB1903 IMPROVEMENT IN PATIENT-REPORTED OUTCOMES (PROS) AND FATIGUE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB (IBR) MONOTHERAPY: REPORT OF REAL WORLD EXPERIENCE.

Mela Osorio, M.J.; Pavlovsky, A.; Fernández, I.; More

HemaSphere. 3(S1):867-868, June 2019.

Author:
Sadeghi, F.
Author:
Sadelain, M.

S1634 A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19–28Z/4–1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION

Palomba, M.L.; Batlevi, C.; Riviere, I.; More

HemaSphere. 3(S1):755, June 2019.

Author:
Sadiku, S.
Author:
Saes, J.
Author:
Saevels, K.
Author:
Saez, M. N.
Author:
Safavi, S.
Author:
Sagawa, M.
Author:
saglio, G.

PF405 DASCERN 2-YEAR EXTENDED FOLLOW-UP OF DASATINIB EFFICACY AND SAFETY IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WHO HAVE SUBOPTIMAL RESPONSES TO 3 MONTHS OF IMATINIB

Saglio, G.; Jiang, Q.; Wang, J.; More

HemaSphere. 3(S1):154-155, June 2019.

PF409 DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER STOPPING FRONTLINE (1L) NILOTINIB: ENESTFREEDOM 192-WK RESULTS

Ross, D.M.; Masszi, T.; Gómez Casares, M.T.; More

HemaSphere. 3(S1):157, June 2019.

Author:
Sagüés, M.

PS1171 TELOMERE LENGTH AT DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA PREDICTS THE ACHIEVEMENT OF DEEP MOLECULAR RESPONSE TO IMATINIB

Estrada, N.; Xicoy, B.; García, O.; More

HemaSphere. 3(S1):532-533, June 2019.

Author:
Sagyndikov, G.
Author:
Sahin, D.
Author:
Sahin, F.

PB1933 CLINICAL FEATURES AND TREATMENT OUTCOMES OF CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS IN TURKEY: REAL-WORLD DATA

Saydam, G.; Ünal, A.; Kurtoglu, E.; More

HemaSphere. 3(S1):879, June 2019.

Author:
Sahnane, N.

PS1319 MYD88L265P MUTATION IN WM AND IGM-MGUS: COMPARISON OF FEASIBILITY AND BENEFIT BETWEEN DDPCR AND STANDARD ASQPCR IN CD19+ SELECTED AND UNSELECTED SAMPLES

Drandi, D.; Furlan, D.; Ferrante, M.; More

HemaSphere. 3(S1):602, June 2019.

Author:
Sahoo, S.
Author:
Said, D.
Author:
Saiki, R.

S135 NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3(S1):19-20, June 2019.

Author:
Sail, K.

PF381 FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT-NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY

Rhodes, J.; Sail, K.; Sarraf Yazdy, M.; More

HemaSphere. 3(S1):142, June 2019.

Author:
Saillard, C.
Author:
Saini, L.

PF587 SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Chen, C.; Gasparetto, C.; White, D.; More

HemaSphere. 3(S1):245, June 2019.

PS1414 A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Gasparetto, C.; Lentzsch, S.; Schiller, G.; More

HemaSphere. 3(S1):650, June 2019.

S1606 SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS

Gasparetto, C.; Lentzsch, S.; Schiller, G.; More

HemaSphere. 3(S1):740, June 2019.

Author:
Sait, S.
Author:
Saito, A.

PF301 REDUCED-INTENSITY IMMUNOCHEMOTHERAPY WITHOUT VINCRISTINE IN ELDERLY PATIENTS OLDER THAN 80 YEARS OLD WITH DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTRE, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL

Yoshida, I.; Suehiro, Y.; Hirabayashi, Y.; More

HemaSphere. 3(S1):102-103, June 2019.

Author:
Saito, K.

S118 IMPACT OF PRE-TRANSPLANT DONOR-SPECIFIC ANTI-HLA ANTIBODIES IN CORD BLOOD TRANSPLANTATION ON BEHALF OF THE TRANSPLANT COMPLICATIONS WORKING GROUP OF JSHCT

Fuji, S.; Oshima, K.; Ohashi, K.; More

HemaSphere. 3(S1):11, June 2019.

Author:
Saito, R.
Author:
Saitoh, T.